Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study
-
Published:2017-11
Issue:
Volume:85
Page:39-48
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Ravaud AlainORCID,
Gomez-Roca Carlos,
Picat Marie-Quitterie,
Digue Laurence,
Chevreau Christine,
Gimbert Anne,
Chauzit Emmanuelle,
Sitta Rémi,
Cornelis François,
Asselineau Julien,
Aziza Richard,
Daste Amaury,
Quemener Cathy,
Baud Jessica,
Bikfalvi Andréas,
Pedenon–Périchout Delphine,
Doussau Adelaïde,
Molimard Mathieu,
Delord Jean-Pierre
Subject
Cancer Research,Oncology
Reference32 articles.
1. Angiogenic inhibitors: a new therapeutic strategy in oncology;Gasparini;Nat Clin Pract Oncol,2005
2. Nonclinical anti-angiogenesis and anti-tumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3;Hu-Lowe;Clin Cancer Res,2008
3. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial;Rini;Lancet,2011
4. Targeting von Hippel-Lindau pathway in renal cell carcinoma;Patel;Clin Cancer Res,2006
5. mTOR inhibitor RAD001 (everolimus) has anti-angiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor;Lane;Clin Cancer Res,2009
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献